

New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Buprenorphine Depot Injection (Brixadi™)	Opioid Agonist	Treatment of Opioid Addiction	FDA review pending.
Oxycodone (Aximris XR™)	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Meloxicam/Rizatriptan	NSAID/Serotonin Agonist	Migraine Headache	FDA review pending.

Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Dabigatran (Pradaxa®)	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	First patent set to expire December 2021. Generic anticipated June 2022.
Oxycodone HCl (Oxaydo®)	Opioid Agonist	Pain	Generic exclusivity anticipated in 2022.
Apixaban (Eliquis®)	Anticoagulant	Treatment/Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.

Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Nalmefene Injection	Opioid Antagonist	Opioid Overdose	June 2022
Baclofen Granules (Lyvispah®)	Muscle Relaxant	Muscle Spasticity	June 2022
Naloxone Injection (Zimhi™)	Opioid Antagonist	Opioid Overdose	March 2022
Celecoxib/Tramadol (Seglentis®)	NSAID/Opioid Agonist	Pain	March 2022
Baclofen Oral Suspension (Fleqsuvy™)	Muscle Relaxant	Muscle Spasms	March 2022
Celecoxib Oral Liquid (Elyxyb™)	NSAID	Migraine Headache Treatment	February 2022
Naloxone Nasal Spray (Kloxxado™)	Opioid Antagonist	Opioid Overdose	August 2021

Report

Monthly New Drug and First Time Generic June 2022



Available in the Last 12 Months

Newly Available Generics

Vilazodone (Viibryd®)	Antidepressant	Depression	June 2022
Diclofenac Sodium 2% (Pennsaid®) Solution	Topical NSAID	Pain	May 2022
Diclofenac Potassium (Zipsor®) Capsule	NSAID	Pain	March 2022
Naloxone HCl (Narcan®) Nasal Spray	Opioid Antagonist	Opioid Overdose	December 2021
Zolmitriptan Nasal Spray (Zomig®)	Serotonin Agonist	Migraine Headache Treatment	November 2021
Nebivolol (Bystolic®)	Beta Blocker	High Blood Pressure	September 2021
Ibuprofen/Famotidine (Duexis®)	NSAID/H-2 Receptor Antagonist	Pain/Inflammation	August 2021

Discontinuations & Withdrawals

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Hydrocodone ER Capsules (Zohydro® ER)	Opioid Antagonist	Pain	Manufacturer has stopped distribution and FDA has rescinded approval effective February 2022.